Sex disparities in myelodysplastic syndromes: genotype, phenotype, and outcomes

There is limited research on the influence of sex on genotype, phenotype, and health outcomes of patients diagnosed with myelodysplastic syndromes (MDS). Prognostic models 1-4 used in clinical practice help guide treatment selection and patient education. There are multiple models with differing variables, highlighting the limitations of accurately predicting disease progression and survival. Current models do not include sex as a variable to further inform prognosis and treatment selection. Sex, as a biological variable, is determined by the presence or absence of the Y chromosome, hormones, and gene expression.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 16, 2023 Category: Hematology Authors: Sara M Tinsley-Vance, Najla Al Ali, Somedeb Ball, Luis E Aguirre, Akriti G Jain, Mohammad Omar Hussaini, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey Lancet, Eric Padron, David A Sallman, Rami S Komrokji Tags: Original article Source Type: research